β-triketone acyl derivatives for Fusarium disease control

Overview

This research investigates β-triketone acyl derivatives as antifungal agents for controlling pathogenic Fusarium species, which cause significant crop diseases worldwide. The work centers on understanding how the keto-enol moiety of β-triketones influences their ability to inhibit Fusarium pathogens. Prior research demonstrated substantial Fusarium disease reduction when banana plants were treated with β-triketone (tasmanone)-rich Eucalyptus cloeziana mulch, and synthesized β-triketones with different keto-enol substituents showed varying inhibition of the indicator ascomycete Candida albicans. This research aims to identify the most effective β-triketone variants for agricultural disease management.

Technical specifications

Key compounds under investigation:

• Flavesone (2.8 g at 99% purity, synthesized)
• Leptospermone (2.2 g at 96% purity, synthesized)
• Isoleptospermone (2.4 g at 98% purity, synthesized)
• Tasmanone (5.6 g at 98% purity, extracted from E. cloeziana leaf distilled oil)

Research approach:

• Stage 1: Synthesis of β-triketones with diverse paraffinic acyl substituents, plus examination of novel acyl substituents extracted from Eucalyptus or Backhausia leaves
• Stage 2: Testing of synthesized products and β-triketone-rich oil extracts for anti-F. oxysporum activity using well-plated bioassays, followed by greenhouse pot trials to evaluate disease control effects
• Preliminary C. albicans inhibition results: leptospermone 5.5%, tasmanone 3.2%, flavesone 2.66%, and isoleptospermone 2.24%

Key insight: Leptospermone's isobutyryl acyl group and tasmanone's mono-unsaturated hexacyclic group create keto-enol environments that differ from those of isoleptospermone and flavesone, potentially explaining their differential antifungal activity.

Technology readiness level

This research is at an early experimental stage. Prior validation has demonstrated proof-of-concept through C. albicans antifungal susceptibility testing and field observation of disease reduction using tasmanone-rich mulch. The planned one-year research program will progress from synthesis through laboratory bioassays to greenhouse pot trials. Most project expenses are allocated to laboratory consumables and field-testing materials. The research is positioned to generate candidates for further agricultural field validation and potential development as biofungicide products.